The expression of prostate-specific membrane antigen in intraductal carcinoma of the prostate
To investigate the immunohistochemical expression of prostate-specific membrane antigen (PSMA) and radiological parameters of [<sup>68</sup>Ga]Ga-PSMA-11-PET/CT of intraductal carcinoma of the prostate (IDC-P). Seventy men with prostate cancer who had preoperative [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT scan and following radical prostatectomy were retrospectively included. Radiological parameters including maximal tumor diameter, mean standard uptake value (SUV<sub>mean</sub>), and maximal standard uptake value (SUV<sub>max</sub>) were derived from PET/CT images. Immunohistochemistry was used to determine the PSMA expression of IDC-P. The Mann-Whitney U test was performed for continuous variables and the chi-squared test for categorical variables. Logistic regression model was used for univariate analysis to compare the correlation between IDC-P and different preoperative variables. A total of 93 lesions were identified in 70 patients. Of these lesions, 21 (22.6%) in 20 patients (28.6%) were found to accompany IDC-P. The immune response score (IRS) of IDC-P lesions was significantly lower than that of prostate adenocarcinoma (P = 0.004).In multivariate analysis, SUV<sub>mean</sub> was found to be significantly lower in patients/lesions with IDC-P (P = 0.011, OR: 0.797 [95% CI 0.669-0.948] in the per-patient analysis and P = 0.028, OR: 0.829 [95% CI0.701-0.980] in the per-lesion analysis, respectively). SUV<sub>mean</sub> showed considerable AUC value of 0.71 (95% CI 0.589-0.839) in the per-patient analysis. Our results indicated lower histopathological PSMA expression and reduced [68Ga]Ga-PSMA-11 uptake in IDC-P compared to conventional prostate adenocarcinoma, suggesting that IDC-P may exhibit distinct biological features and could offer new insights for the radiological detection of intraductal carcinoma of the prostate in clinical practice.
Authors
- Xuefeng Qiu (ORCID: https://orcid.org/0000-0002-3554-5145)
- Fengjiao Yang (ORCID: https://orcid.org/0000-0002-7217-4953)
- Junlong Zhuang (ORCID: https://orcid.org/0000-0001-5150-3669)
- Shuyue Ai
- Hongqian Guo (ORCID: https://orcid.org/0000-0002-3121-5157)
- Zheng Han (ORCID: https://orcid.org/0000-0002-9424-5759)
- Yao Fu (ORCID: https://orcid.org/0000-0001-9864-1030)
- Binyu Wang (ORCID: https://orcid.org/0000-0002-9471-9256)
- Shan Peng (ORCID: https://orcid.org/0000-0002-4432-6008)
- Feng Wang
Institutions
- Nanjing Drum Tower Hospital (CN)
- Nanjing Xiaozhuang University (CN)
- Nanjing Medical University (CN)
- Nanjing University (CN)
Publication Details
- Journal
- Scientific Reports
- Published
- 2025-10-09
- DOI
- https://doi.org/10.1038/s41598-025-19283-1
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Government of Jiangsu Province
- Natural Science Foundation of Jiangsu Province
- Nanjing Medical Science and Technique Development Foundation